Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-glypican 3 chimeric antigen receptor T cell therapy - CARSgen

Next Previous
Drug Profile

Anti-glypican 3 chimeric antigen receptor T cell therapy - CARSgen

Alternative Names: Anti glypican 3 chimeric antigen receptor T cell therapy - CARSgen; anti-GPC3 CAR T; Anti-GPC3 chimeric antigen receptor T cell therapy – CARsgen; CAR-GPC3 T-cell; CT-011 - CARSgen; Glypican-3-chimeric-antigen-receptor-T-cell-therapy; GPC3-CAR-T cell therapy - CARSgen; GPC3-CAR/CSG-GPC3

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CARsgen
  • Developer CARsgen; Shanghai Jiao Tong University
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver cancer
  • No development reported Breast cancer; Gastric cancer; Lung cancer

Most Recent Events

  • 15 Jan 2024 CARsgen plans clinical trial for Liver cancer in China
  • 15 Jan 2024 National Medical Products Administration (NMPA), China approves IND application for Anti-glypican 3 chimeric antigen receptor T cell therapy in Liver cancer
  • 16 Oct 2023 Efficacy data from a phase I trial in liver cancer released by CARsgen Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top